Ionis Pharmaceuticals IONS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's EPS (diluted)?
- Ionis Pharmaceuticals (IONS) reported EPS (diluted) of -$0.56 in Q1 2026.
- How has Ionis Pharmaceuticals's EPS (diluted) changed year-over-year?
- Ionis Pharmaceuticals's EPS (diluted) increased by 39.8% year-over-year, from -$0.93 to -$0.56.
- What is the long-term trend for Ionis Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's EPS (diluted) has grown at a 59.2% compound annual growth rate (CAGR), from -$0.38 to -$2.44.
- What does EPS (diluted) mean?
- Profit per share calculated by including all potential shares that could be issued.
- How do you interpret EPS (diluted)?
- An increase suggests growing profitability per share, while a decrease indicates earnings dilution or declining performance.
- How does EPS (diluted) compare across companies?
- Standard valuation metric used by investors to compare profitability across companies with different share counts.